Loading...
Loading...
ME| Name | Value |
|---|---|
| Revenues | 40.4M |
| Cost of Revenue | 19.9M |
| Gross Profit | 20.5M |
| Operating Expense | 86.7M |
| Operating I/L | -72.0M |
| Other Income/Expense | 2.6M |
| Interest Income | 2.6M |
| Pretax | -69.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -69.4M |
23andMe Holding Co. operates as a consumer genetics testing company, offering genetic reports on ancestral origins, health risks, and carrier conditions. Its saliva-based genetic testing kit provides insights into medication responses. The company also focuses on drug development and therapies for oncology, respiratory, and cardiovascular diseases. Additionally, it engages in out-licensing of intellectual property related to drug targets. Through a collaboration with GlaxoSmithKline, it validates, develops, and commercializes drugs based on genetic insights. The company generates revenue through consumer genetic testing services and drug development activities.
